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Molecular surveillance of newly diagnosed HIV-infections is important for tracking trends in
circulating HIV-variants, including those with transmitted drug resistances (TDR) to sustain
ART efficacy.
Methods
Dried serum spots (DSS) are received together with the statutory notification of a new diag-
nosis. ’Recent infections’ (<155 days) classified by a ’recent infection test algorithm’ (BED-
CEIA and clinical data) are genotyped in HIV-protease (PR), reverse transcriptase (RT) and
integrase (INT) to determine the HIV-1 subtype, to calculate prevalence and trends of TDR,
to predict baseline susceptibility and to identify potential transmission clusters for resistant
variants.
Results
Between January 2013 and December 2016, 1,885 recent infections were analysed regard-
ing the PR/RT genomic region, with 43.5% of these also being subjected to the analysis of
INT. The proportion of HIV-1 non-B viruses (31.3%; 591/1,885) increased from 21.6% to
36.0%, particularly the subtypes A (5.0% to 8.3%) and C (3.2% to 7.7%; all ptrends < 0.01).
The subtype A increment is mainly due to transmissions within men who have sex with men
(MSM) while subtype C transmissions are associated with heterosexuals and people who
inject drugs. The prevalence of TDR was stable at 11.0% (208/1,885) over the study period.
Resistances to nucleotide RT inhibitors (NRTI) and PR inhibitors (PI) were 4.5% and 3.2%,
respectively, without identifiable trends. In contrast, resistances to non-NRTIs (NNRTI,
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4.7%) doubled between 2014 and 2016 from 3.2% to 6.4% (ptrend = 0.02) mainly due to the
K103N mutation (from 1.7% to 4.1%; ptrend = 0.03) predominantly detected in recently
infected German MSM not linked to transmission clusters. Transmitted INSTI mutations
were present in only one case (T66I) and resistance to dolutegravir was not identified at all.
Reduced susceptibility to recommended first-line therapies was low with 1.0% for PIs, 1.3%
for NRTIs and 0.7% for INSTIs, but high for the NNRTIs efavirence (4.9%) and rilpivirine
(6.0%) due to the K103N mutation and the polymorphic mutation E138A. These trends in
therapy-naïve individuals impact current first-line regimens and require awareness and vigi-
lant surveillance.
Introduction
HIV infection is still a major public health concern in EU/EEA countries with approximately
30,000 new cases reported each year [1]. Prevention by pre-exposure prophylaxis (PrEP), fre-
quent (self-) testing of persons at risk with rapid diagnostic assays and immediate initiation of
highly effective combination antiretroviral therapy (cART) following a confirmed infection
are among the most promising new measures introduced in recent years to curb the number
of HIV-transmissions in this region of the world [2]. However, further transmission of drug
resistant viral variants that can limit the success of first-line therapy regimens remains a sub-
stantial issue [3]. Genotypic resistance testing prior to treatment initiation is therefore recom-
mended by national and European guidelines in order to predict clinical resistance and guide
the choice of individual treatments [4, 5]. The prevalence of transmitted drug resistance
(TDR) is primarily linked to the cART prescription pattern in a country, the proportion of
individuals treated with cART, the extend of acquired drug resistance relaying on the common
therapy adherence, resistance barriers of the administered antiretroviral regimes and the fre-
quency of virus load monitoring. As the access to cART is increasing worldwide [6], TDR
requires more attention and its surveillance is gaining momentum at national and interna-
tional levels [7–9].
To predict TDR in cART-naïve patients, the World Health Organization (WHO) defined
relevant resistance mutations selected by protease inhibitors (PIs), nucleoside reverse tran-
scriptase inhibitors (NRTIs) and non-NRTIs (NNRTIs). These are summarized in the WHO
surveillance drug resistance mutations (WHO SDRM) list from 2009 [10]. Based on this list,
the overall prevalence of TDR in Europe is reported to have been largely stable for more than a
decade, affecting approximately one in ten new infections [11, 12]. This is somewhat surpris-
ing since the introduction of new drugs with higher potency and reduced tendency to induce
resistance resulted in a decrease in therapy failures during this period [13]. The explanation
for this apparent paradox is the high prevalence of resistance associated mutations with low
impact on viral fitness that persist in transmission chains for years without selective pressure
by the drug [14–16].
The surveillance of transmitted resistances of integrase strand transfer inhibtors (INSTI) is
of particular interest. Raltegravir was approved in Europe in 2007, followed by elvitegravir
(2012) and dolutegravir (2014). The general tolerance and the low likelihood of resistance
selection due to a high genetic barrier [17] led to their widespread use and recommendation as
first-line option in European guidelines [5, 18]. Since the WHO SDRM list does not include
INSTI selected mutations in the last updated version of 2009, the Stanford HIV drug resistance
database SDRM Worksheet for INSTI may be used instead.
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In 2013 a molecular surveillance program was initiated in Germany that is based on the
examination of viral sequences from recently infected among newly diagnosed HIV cases [7,
19]. The aim of the present study was to analyse the distribution of HIV-1 subtypes, the preva-
lence of TDR, the potential phylogenetic relationship of TDR and its impact on the baseline
susceptibility in newly diagnosed patients between 2013 and 2016.
Materials and methods
Clinical samples
According to the “Protection Against Infection Act” (IfSG; §7) of 2001, diagnostic laboratories
in Germany are obligated to report newly diagnosed HIV infections anonymously to the Ger-
man public health institute (Robert Koch Institute, RKI). For surveillance programs a network
of approximately eighty diagnostic laboratories (https://www.rki.de/DE/Content/InfAZ/H/
HIVAIDS/Studien/InzSurv_HIV/beteiligte_Labore.html) was established that send along with
the report form, residual serum from newly diagnosed HIV cases spotted onto a filter card
(Whatman 903 filter paper) as dried serum spots (DSS). According to §13 of IfSG the RKI is
authorized to receive blood residuals from diagnostics for surveillance purposes.
By this sampling strategy, specimens from approximately 60% of all reported newly diag-
nosed HIV infections are send to the RKI laboratory. Here, DSS are classified into recently
acquired and long term HIV-infections according to the ECDC recommended ‘recent infec-
tion test algorithm´ (RITA) including results from the BED IgG Capture EIA (Sedia Biosci-
ences Corporation, Portland, OR, USA) and clinical data from the HIV-notification database
(CDC classification, CD4 cell count and viral load) [19]. Only recent infections are subse-
quently processed for HIV-genotyping. Sequence data are finally merged with the provided
anonymous socio-demographic data from the HIV-notification form (gender; transmission
routes: men who have sex with men (MSM), persons with heterosexual contact (HET), people
who inject drugs (PWID); regions of patient origin) for analysis. The data protection officer of
the Robert Koch Institute and the Federal Commissioner for Data Protection and Freedom of
Information approved the study protocol (III-401/008#0016).
HIV-1 subtyping, drug resistance interpretation and phylogenetic analysis
HIV-1 genotypes from the protease (PR) and reverse transcriptase (RT) genomic region
(2013–2016) and the integrase (INT) genomic region (2014–2016) were generated according
to the previously published protocols [20, 21]. Since 2015, Sanger sequencing has been substi-
tuted by next generation sequencing (NGS) using the Illumina MiSeq platform as described
previously [22]. After extensive evaluations, a 20% threshold for defining ambiguities was
applied to the NGS generated sequences to maintain consistency (S1 Text).The HIV-1 subtype
was assigned by applying the REGA HIV Subtyping Tool (3.0) [23] and COMET HIV-1 (1.0)
[24] to the pol-sequence. In cases where a subtype or circulating recombinant form (CRF)
could not be assigned, a maximum-likelihood tree with bootstrap (IQ-TREE 1.5.5) was calcu-
lated using the HIV-1 subtype reference panel from the Los Alamos HIV sequence data base.
Only subtype classifications based on bootstrap values of>70% in the tree topology were
taken into account, otherwise they were classified as unique recombinant form (URF).
The prevalence of TDR was calculated from the number of persons infected with viral vari-
ants carrying at least one mutation included in the WHO SDRM list [10]. Transmitted INSTI
mutations were defined as the detection of mutations listed in the Stanford HIV drug resis-
tance database SDRM Worksheet for INSTI (https://hivdb.stanford.edu/pages/SDRM.
worksheet.INI.html; updated in June 2016). Phenotypic resistance was predicted using the
Stanford HIV Drug Resistance Database 8.4 algorithm (Stanford HIVbd) [25]. Three levels of
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resistance were scored: (i) S = susceptible (including susceptible and potential resistant levels)
(ii) I = intermediate (including low and intermediate levels) and (iii) R = resistant (high
level resistance). Predictions of primary resistance to recommended and alternative first-
line therapy options are based on the EACS treatment guidelines 9.0 [5] which include the
NNRTIs efavirenz and rilpivirine, the NRTIs abacavir, lamivudine, tenofovir and emtricita-
bine, the PIs atazanavir, darunavir and lopinavir and the INSTIs raltegravir, elvitegravir and
dolutegravir.
Drug resistance mutations present in a proportion of� 0.5% in the dataset were defined to
be ‘frequent mutations´ and were used for trend analysis. In addition, sequences carrying one
of the ‘frequent mutations´ were applied to phylogenetic analysis to allow the spread of resis-
tance mutations within transmission networks to be mapped. For this purpose sequences were
aligned with 33 reference sequences from the Los Alamos database and trimmed to 1026 base
pairs. To select the optimal tree model, Maximum Likelihood (ML) phylogenies were recon-
structed using the Ultrafast Bootstrap approximation in IQ-TREE with 10,000 replicates with
the integrated model selection algorithm [26, 27]. A group O sequence was used as outgroup
for the ML tree reconstruction. The tool ‘Transmic´ (https://github.com/kavehyousef/code)
[28] was used to identify clusters of closely related sequences, possibly linked by direct trans-
mission or very short transmission chains (putative transmission clusters). Therefore, a 99%
bootstrap cut-off and a 4.5% mean pairwise patristic distance were used as a cluster threshold
as reported by other groups [29, 30]. The tree was visualized in Figtree (version 1.4.0).
Statistics
Statistical analyses were performed using STATA (version 14.2). Continuous variables were
analyzed using median and interquartile range (IQR). The chi2 test was used for bivariate com-
parison and logistic regression to assess the odds ratios (OR) and 95% confidence intervals
(CI). Changes in the prevalence over time were analyzed using the chi2 test for trend of odds.
Results
Characterisation of the study population
Between 2013 and 2016, a total of 10,643 DSS of newly diagnosed HIV-cases were submitted
to the RKI along with the anonymous report and 3,380 (31.8%) were classified as recent infec-
tions. From these we were able to obtain 1,885 (55.8%) HIV-1 genotypes of the PR and RT
genomic regions. The median plasma viral load was 140,500 copies/ml (IQR 32,269–991,106),
the median CD4 cell count was 454 cells/μl (IQR 304–612) and the median age of the newly
diagnosed individuals was 36.3 years. Baseline patient characteristics are shown in Table 1.
During the study period the most remarkable change was an increase in the proportion of
HET (7.6% to 13.1%) and persons with African origin (3.2% to 7.5%) between 2013 and 2015
followed by a slight decline in 2016 (to 11.4% and 6.0%, respectively).
HIV-1 genotypes of the INT genomic region were available for 820 of the 1,885 DSS
(43.5%) from newly diagnosed cases in 2014 (70/466, 16%), 2015 (348/624, 57%) and 2016
(402/517, 79%). The proportional distribution in subgroups was congruent between the total
study population (n = 1,885) and the subset (n = 820) (Table 1).
Prevalence and trends of HIV-1 subtypes
Subtype B infections were predominant in the total study population with 68.6% (CI95% 66.5–
70.7; 1,294/1,885) and primarily affected MSM and persons of German origin (Fig 1, Table 2).
The proportion of subtype B infections was significantly decreasing from 78.4% in 2013 to
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Table 1. Baseline characteristics of the study population.
Protease/Reverse Transcriptase Integrase
n 2013–2016 (n = 1,885)
%
2013 (n = 278)
%
2014 (n = 466) % 2015 (n = 624)% 2016 (n = 517)
%
2014–2016 (n = 820)
%
Gender
Male 1,638 86.9 87.8 88.6 87.0 84.7 87.2
Female 228 12.1 11.5 10.7 12.3 13.4 11.8
Not reported 19 1.0 0.7 0.6 0.6 1.9 1.0
Mode of transmission
MSM 1,091 57.9 60.8 62.5 55.6 54.9 55.5
HET 207 11.0 7.6 9.7 13.1 11.4 10.7
PWID 71 3.8 4.0 2.2 4.3 4.5 5.2
Other 7 0.4 0.7 0.4 0.3 0.2 0.4
Not reported 509 27.0 27.0 25.3 26.6 29.0 28.2
Region of origin
Germany 1,147 60.9 59.4 60.7 56.6 66.9 61.3
Eastern Europe 59 3.1 2.5 4.1 3.2 2.5 2.9
Western Europe 60 3.2 4.7 2.6 4.2 1.7 3.3
Central Europe 77 4.1 3.2 4.7 3.7 4.5 4.8
Asia/Oceania 36 1.9 1.4 2.4 2.9 0.6 1.7
America/Caribbean 46 2.4 2.5 2.2 3.2 1.7 2.4
Africa 111 5.9 3.2 5.2 7.5 6.0 6.1
Other 8 0.4 0.4 0.2 0.5 0.6 0.5
Not reported 341 18.1 22.7 18.0 18.3 15.5� 17.0
MSM: men who have sex with men; HET: persons with heterosexual mode of transmission; PWID: people who inject drugs
� p <0.05.
https://doi.org/10.1371/journal.pone.0206234.t001
Fig 1. Analysis of HIV-1 subtypes. (A) Proportion of HIV-1 subtypes in the study population. (B) Trend analysis for
major subtypes that show a significant increase or decrease (p< 0.05) between 2013 and 2016. Trend lines and p-
values are indicated for the total proportions of subtypes. MSM: men who have sex with men; HET: persons with
heterosexual mode of transmission, PWID: people who inject drugs, GER: German.
https://doi.org/10.1371/journal.pone.0206234.g001
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64.0% in 2016 (ptrend = 0.001). This trend is primarily based on the two above mentioned sub-
groups and can also be observed in non-Germans (all ptrend> 0.05) (Fig 1B).
Among the non-B infections (31.4%, CI95% 29.3–33.5, 591/1,885) the most prevalent were
subtype A (8.2%), CRF02_AG (5.7%) and subtype C (5.0%) (Fig 1A). Almost half of the
infected individuals were of German origin, while the other half was of foreign origin
(Table 2). Subtype A infected persons of foreign origin (n = 60) mostly originated from Cen-
tral/East Europe (n = 31) or Sub-Saharan Africa (n = 13) and subtype C or CRF02_AG infected
persons of foreign origin (nC = 40 and nAG = 48) largely originated from Sub-Saharan Africa
(nC = 26 and nAG = 21) (Table 2). The increment in the proportion of non-B infections is
mostly due to a significant increase of subtype A (ptrend = 0.008) and C (ptrend = 0.002) (Fig
1B). While subtype A peaked in 2015 and declined somewhat in the following year, subtype C
proportions increased steadily and reached a maximum in 2016. These developments are also
evident in most of the analysed subgroups except for subtype C in non-Germans, which
peaked in 2015 (Fig 1B).
Prevalence and trends of TDR
The overall prevalence of TDR according to the WHO SDRM list was 11.0% (CI95% 9.7–12.5)
(Table 3). There was little variation in the four year period between 2013 and 2016 (ptrend = 0.68)








Subtype C (n = 95)
%
MSM 68.7 36.4 22.2 26.3
PWID 2.0 8.4 7.4 10.5
HET 3.3 24.7 32.4 36.9
Not reported/ other 26.0 30.5 38.0 26.3
Germany 68.9 43.5 32.4 43.2
Not Germany 13.7 39.0 44.4 42.1
Not reported 17.4 17.5 23.2 14.7
MSM: men who have sex with men; HET: persons with heterosexual mode of transmission, PWID: people who inject drugs
https://doi.org/10.1371/journal.pone.0206234.t002
Table 3. Prevalence of TDR within subgroups between 2013 and 2016.
Over all
% (n)























































NRTI 4.5 (84) 4.4 (48) 3.4 (7) 2.8 (2) 5.2 (27) 4.4 (51) 2.6 (5) 4.3 (2) 6.3 (7) 2.8
(1)
5.2 (18) 1.9 (3) 5.7 (74) 3.2
(3)
1.9 (2)




5.2 (18) 5.2 (8) 4.9 (63) 5.3
(5)
5.6 (6)
PI 3.2 (60) 3.7 (40) 0.5 (1) 1.4 (1) 3.5 (18) 3.5 (40) 1.0 (2) 0.0 (0) 2.7 (3) 2.8
(1)
4.0 (14) 9.1 (14) 3.2 (41) 2.1
(2)
0.9 (1)
MSM: men who have sex with men; HET: persons with heterosexual mode of transmission; TM: mode of transmission; rep.: reported; GER: Germany; EUR: Europe;
AM: America; AFR: Africa; AS: Asia
https://doi.org/10.1371/journal.pone.0206234.t003
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(Fig 2). Mono resistance was present in 9.9% of the patients (NNRTI: 3.6%, NRTI: 3.4%, PI:
2.8%), dual and triple class resistance in 1.0% and 0.2%, respectively. Taking mono and multiclass
TDR together (cumulative counts), NNRTI resistance was most frequently found with 4.7%
(CI95% 3.9–5.8), followed by NRTI resistance (4.5%, CI95% 3.6–5.5), and PI resistance (3.2%,
CI95% 2.5–4.1) (Table 3). A trend analysis revealed that NRTI resistance decreased to its lowest
levels in 2016 (ptrend = 0.47), while NNRTI resistance increased within the study period (ptrend =
0.06). This increase was significant between 2014 and 2016 (ptrend = 0.02). PI resistance did not
show any tendency to increase or decrease between 2013 and 2016 (ptrend = 0.99) (Fig 2).
Significantly higher proportions of TDR were found in MSM compared to HET (p = 0.03)
and in Germans compared to non-Germans (33/397, 8.3%; p< 0.13). However, the prevalence
was also high in persons with American and African origin, but the total number of cases with
this origin was low (n = 6 and 14, respectively) (Table 3). Moreover, in subtype B the preva-
lence of TDR (160/1,294; 12.4%) was significantly higher than in non-B subtypes (48/591;
8.1%; p< 0.01). However, the highest level of TDR (14.9%) was identified in subtype A
(Table 3).
Prevalence of TDR mutations and their impact on drug susceptibility
according to the Stanford HIVdb
The thymidine analogue mutations (TAMs) M41L, K219Q and T215 revertants as well as the
non-TAM M184V were among the most frequently transmitted NRTI-resistance mutations
(� 0.5%) (Table 4). These TAMs were responsible for the high proportions of resistance to
zidovudine and stavudine (both 4%) (Fig 3A) at low/intermediate level (Fig 3B). Less fre-
quently observed were the mutations D67N (n = 8), K65R (n = 2) and K70R (n = 2). The
M184V, K70R and K65R mutations induce high level resistance to NRTIs in recommended
first-line regimen according to EACS (9.0). However, their abundance was low with 1.3% (aba-
cavir 1.3%, lamivudine 0.7%, tenofovir 0.9% and emtricitabine 0.7%) (Fig 3A).
Fig 2. Trends of transmitted drug resistance among newly diagnosed HIV cases with recent HIV infections in total and according to drug classes. The
confidence interval for NNRTI resistance is indicated.
https://doi.org/10.1371/journal.pone.0206234.g002
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The most frequently detected NNRTI-mutation was K103N. Its proportion was increasing
between 2013 and 2016 (ptrend = 0.07) with this increase being significant between 2014 and
2016 (ptrend = 0.03). The steep slope of the ‘total K103N´ between 2014 and 2016 was quite con-
gruent in the subgroups of MSM, persons of German origin and subtype B infections (Fig 4A).
However, slightly increasing tendencies with a peak in 2015 could also be observed for persons
with non-German origin and subtype non-B infections (Fig 4B). Consequently, resistance to
first generation NNRTIs (efavirenz and nevirapine) doubled between 2014 and 2016 (Fig 3A).
The polymorphic NNRTI-mutation E138A not recorded in the SDRM list but associated with
low level resistance to the second generation NNRTI rilpivirine according to Stanford HIVdb
was found even more frequently during the whole study period (Table 4 and Fig 3B). There-
fore, phenotypic resistance to the first-line recommended or alternative NNRTIs (efavirenz
4.9% and rilpivirine 6%) (Fig 3A) was relatively high with 9.1% (172/1,885).
PI-mutations M46I/L and V82L that are responsible for low or intermediate resistance lev-
els to tipranavir, nelfinavir and fosamprenavir (Fig 3B) were also frequently present (Table 4)
but without identifiable tendency during the study period (Fig 3A). However, for the first-line
recommended or alternative PIs predicted phenotypic resistance was very low with 1% (ataza-
navir 0.7% and lopinavir 1.0%).
Transmitted INSTI mutations according to Stanford SDRM Worksheet for INSTI were
identified in a single sequence among 820 analysed cases (0.12%), namely the major primary
mutation T66I resulting in high level resistance to elvitegravir and low level resistance to ralte-
gravir. According to predictions from the Stanford HIVdb, phenotypic INSTI resistance
(excluding potential low level) was identified in 0.7% (6/820) of cases (Fig 3B) due to the pres-
ence of the T66I (n = 1), the G163R or K (n = 4) or the combination of T97A and E157Q
(n = 1) resulting in low level resistance to elvitegravir and raltegravir. These cases were absent
in 2014, but exhibited an increase to 0.3% (1/624) in 2015 and to 1.2% (5/517) in 2016 (Fig
3A). None of the sequences showed evidence for resistance to dolutegravir (Fig 3). Taken
together, primary resistance to recommended drugs for first-line therapy according to EACS
9.0 was 10.9% (205/1,885).
Table 4. Most frequently identified TDR mutations (� 0.5%) within the year of diagnosis and indoors HIV-1 subtypes.










M41L 21 1.1 1.4 1.5 1.0 0.8 0.6 1.5 - -
M184V 9 0.5 0.7 0.2 0.8 0.2 0.6 0.3 2.1 0.9
T215rev 49 2.6 1.4 3.0 2.9 2.5 0.6 3.7 - -
K219Q 12 0.6 0.7 0.6 1.0 0.2 1.3 0.6 1.1 0.9
NNRTI
K103N 57 3.0 3.2 1.7 3.0 4.1 3.2 3.4 3.2 2.8
�V108I 9 0.5 1.4 0.2 0.2 0.6 0.6 0.5 - -
�E138A 75 4.0 4.7 4.3 3.8 3.5 6.5 3.5 3.2 5.6
PI
M46I/L 28 1.5 2.2 1.3 1.0 1.9 7.8 1.1 1.1 0.9
Q58E 10 0.5 1.4 - 0.3 0.8 - 0.8 - -
V82L 15 0.8 0.7 0.6 0.8 1.0 - 1.2 - -
L90M 9 0.5 0.7 0.6 0.5 0.2 - 0.6 - -
� mutations according to Stanford HIVdb, not listed in the SDRM-list
https://doi.org/10.1371/journal.pone.0206234.t004
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Fig 3. Prevalence of predicted resistance to approved HIV therapeutics according to the Stanford HIVdb. (A) Resistance (low/intermediate/high
level) stratified according to the year of diagnosis. (B) Resistance level; # calculated from 820 cases;� drugs included in recommended and alternative
first-line treatment option according to EACS 9.0 guidelines; EFV efavirenz, ETR etravirine, NVP nevirapine, RPV rilpivirine, 3TC lamivudine, ABC
abacavir, AZT zidovudine, D4T stavudine, DDI didanosine, FTC emtricitabine, TDF tenofovir, ATV atazanavir, DRV darunavir, FPV fosamprenavir,
IDV indinavir, LPV lopinavir, NFV nelfinavir, SQV saquinavir, TPV tipranavir, EVG elvitegravir, RAL raltegravir, DTG dolutegravir.
https://doi.org/10.1371/journal.pone.0206234.g003
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Transmission cluster analysis of TDR mutations
Sequences that had one or more of the most frequent NRTI, NNRTI and PI resistance mutations
or the polymorphic E138A (listed in Table 4) were selected for phylogenetic analysis (n = 251). All
relevant sequence data have been deposited in the NCBI database. All 251 accession numbers are
provided within the Supporting Information file, S2 Text. Among them, half were found in one of
32 clusters identified (49.4%, 124/251). The average was 3.9 (min 2 –max 16) sequences per clus-
ter. Three large clusters consisting exclusively of male individuals and mainly MSM and Germans
were recognized. Cluster 1 consists of 11 subtype A sequences with the M46I mutation. 15 subtype
B sequences with the V82L mutation form cluster 2 and 16 subtype B sequences with the revertant
T215S form the third large cluster (Fig 5). The proportion of these major TDR mutations trans-
mitted in clusters and the respective cluster sizes are given in Table 5.
Special attention was paid to the clustering of the K103N mutation in order to analyse
whether the previously described increase in 2015/2016 was the result of a recent spread within
one or few active transmission networks and/or within a specific transmission group. Around
40% of the sequences carrying the K103N mutation were found within nine different clusters
(all subtype B, cluster size of 2–4 sequences per cluster) (Table 5, Fig 5). Persons in this ‘clus-
ter-linked´ group were all male, MSM and German or their transmission group and/or origin
was not reported. The proportion of individuals within ‘cluster-linked´ subgroups was quite
similar in the years 2013/2014 and 2015/2016 (p = 0.67). Among the ‘not cluster-linked´
sequences carrying the K103N mutation the diversity of HIV-1 subtypes (A, B, C, G,
Fig 4. Trends for the K103N mutation between 2013 and 2016 in total and in subgroups. (A) in MSM, persons with German Origin or subtype B infection
(B) in persons with heterosexual transmission route, with non-German origin and with subtype non-B infection. Trend line and p-value are indicated for
proportions of total K103N. MSM: men who have sex with men.
https://doi.org/10.1371/journal.pone.0206234.g004
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CRF02_AG) as well as the origin of infected persons (Germany, East Europe, West Europe,
Latin America, Sub Saharan Africa and not reported) was much higher. The proportion of
individuals not linked to K103N-clusters was generally higher in 2015/2016 than in 2013/2014
(p = 0.01), although the sampling was more dense in 2015/2016 (n = 1,141 compared to 744 in
2013/2014). Especially the group of ‘male persons´ and here particularly those for which the
transmission route was not reported was significantly higher in 2015/2016 (p = 0.008) (Fig 6).
However, insignificantly higher proportions were also present in MSM, Germans, non-Ger-
mans, persons with unknown origin, infected with subtype B as well as non-B infected but
without reaching significance (all p> 0.05) (Fig 6).
Discussion
In this study we analysed 1,885 recent HIV-1 infections newly diagnosed between 2013 and
2016. The proportions of HIV-1 subtypes and primary resistances in the total population and
Fig 5. Phylogenetic analysis of 251 HIV-1 sequences carrying drug resistance mutations. Three large clusters with M46I, V82L or T215S mutations are shown
with blue branches and all sequences carrying the K103N mutation are depicted with dots at the tips.
https://doi.org/10.1371/journal.pone.0206234.g005
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Table 5. Prevalence of mutations identified in clusters by phylogenetic analysis of 251 sequences with drug resistance mutations.
Mutation (n) Proportion in clusters (%) Cluster with 2 individuals Cluster with 3–4 individuals Cluster with 5–7 individuals Cluster with >7 individuals
M46I (20) 75.0 2 - - 1 (n = 11)
M46L (8) 37.5 - 1 - -
V82L (15) 100.0 - - - 1 (n = 15)
L90M (9) 33.3 - 1 - -
Q58E (10) 20.0 1 - - -
K103N (57) 40.4 6 3 - -
V108l (9) 0.0 - - - -
E138A (75) 37.3 2 3 2 -
M41L (21) 42.9 - 1 1 -
M184V (9) 0.0 - - - -
T215E (10) 40.0 2 - - -
T215S (31) 80.6 3 1 - 1 (n = 16)
K219Q (12) 58.3 2 1 - -
https://doi.org/10.1371/journal.pone.0206234.t005
Fig 6. Proportion of not-clusters-linked sequences with K103N mutation according to sub-groups of HIV-infected individuals in 2013/2014
compared to 2015/2016. K103N sequences are grouped according to gender, transmission route, origin and HIV-subtype of the infected person. The
proportion is calculated from the total number of sequences of two respective 2-year periods (2013/2014: 744 sequences; 2015/2016: 1140 sequences).
Between the two year periods a significant increase of the K103N mutation in males who are not linked to transmission clusters is evident. MSM: men
who have sex with men; HET: persons with heterosexual mode of transmission, GER: German, not rep. transm.: not reported transmission, � p< 0.05,
��p< 0.01.
https://doi.org/10.1371/journal.pone.0206234.g006
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within subgroups (mode of transmission, region of origin) were stratified according to the
year of diagnosis to allow analysing changes over time to be.
In Germany, subtype B continues to be the predominant subtype (68.9%), although the pro-
portion of non-B subtypes significantly increased between 2013 and 2016, particularly for sub-
types A and CRF02_AG which peaked in 2015 (11.7% and 7.1%) and subtype C which
doubled from 3.6% in 2013/2014 [7] to 7.7% in 2016. This increase is partly attributed to per-
sons immigrating from countries where these subtypes are highly prevalent [31] (Sub-Saharan
Africa and Central/East Europe) as a result of the flow of refugees into Europe, including Ger-
many with its highest peak in 2015. However, the increase of infections with subtypes A and C
was attributed even more to the spread within the German population: high proportions were
found in German MSM (subtype A) and German HET and PWID (subtype C). A general
increase of non-B subtypes as well as a subtype diversification is a phenomenon that was also
observed for many other European countries [32–34].
TDR in Germany analysed by using the WHO surveillance drug resistance list [10] was sta-
ble at ~11% between 2013 and 2016, which is in agreement with the data from the German
HIV-1 Seroconverter Cohort (11.9% overall TDR in 1996–2010) [35]. TDR at a lower level
(8.3%) has also been calculated across 26 European countries for patients diagnosed between
2008 and 2010. TDR in Germany continues to be more frequent among MSM, as reported for
other European countries [12, 36] and continues to be significantly more frequent in subtype
B than in non-B subtypes. However, the difference appears to be narrowing [37] due to the
increase of TDR in non-B subtypes from 6.4% in a previous study [7] to 8.1% in this study. A
high proportion of TDR was found in subtype A as a result of one German MSM transmission
network spreading the PI resistance mutation M46I. While proportions of NRTI and PI resis-
tance are similar in the present study compared to those reported for Europe [12], the preva-
lence of NNRTI resistance is about two times higher than previously described for Germany
[7] and compared to other countries [12]. This increase was mainly driven by the K103N
mutation selected by the first generation NNRTIs nevirapine and efavirenz. While nevirapine
was removed from the European treatment guidelines several years ago, efavirenz is still listed
as alternative regimen for first-line therapy [5] but is very rarely used in Germany [38]. There-
fore, ’de novo’ selection of K103N mutations in Germany followed by transmission to newly
diagnosed persons seems to be unlikely in times of highly suppressive cART and pre-treatment
resistance testing. In contrast, selection of resistance followed by an alarmingly increasing
trend of TDR—especially for NNRTI resistances—from regions where first generation
NNRTIs are commonly administered due to cost issues (e.g. Sub-Saharan Africa) is reported
[39]. Therefore, we assume that the increase of the K103N mutation in our study population is
the result of two developments: firstly, the import of the K103N mutation with non-B subtypes
from abroad appears to have occurred at quite low levels (Fig 4B). However, the majority of
such imported infections with phylogenetically unrelated viruses, even if reported in Germany
as a “new diagnosis” in the study period, might not have been analysed here because the vast
majority is likely long standing which were excluded from the study.
Secondly, the increasing trend of K103N infections in MSM, individuals of German origin
and with subtype B infection (Fig 4A) might be explained by the fact that German MSM are
known to have the highest rates of recent infections because they test more frequently than
other transmission groups [19]. Although phylogenetic analysis revealed that there was no sig-
nificant spread of K103N within one or more active transmission networks (as shown for the
PI mutations among MSM) we assume that these phylogenetic unrelated K103N carrying
strains are a result of continuous onwards transmission of the persisting K103N mutation
among long term as well as recent infected individuals and therefore, are not appearing as a
coherent transmission network in our phylogenetic analysis. Comprehensive transmission
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network analysis that includes recent as well as long standing infections might therefore pro-
vide some clarification for Germany. Along these lines, increasing proportions of NNRTI
resistance and particularly of the K103N mutation were also reported from MSM networks in
Greece and in San Diego [40, 41].
Large transmission networks of German MSM were observed for the most frequently trans-
mitted NRTI mutation T215S (revertant of T215Y/F), and the PI resistance mutations M46I
and V82L. Nevertheless, the proportions of transmitted NRTI and PI resistance remained sta-
ble during the study period. NRTI resistance resulted mainly from the high prevalence of per-
sisting TAMs. Many studies have shown by phylogenetic analysis that onward transmission
among drug-naïve patients is the major reason for the maintenance of stable NRTI resistance
levels [41–45]. However, as the TAM selecting drugs zidovudine and stavudine have been
replaced by tenofovir in current treatment guidelines, TAMs are no longer of direct clinical
relevance. The proportion of transmitted PI resistance was higher in Germany (3.2%) than in
other European countries (2.0%) [12], presumably due to large clusters of the M46I and V82L
mutations. However, their impact on PIs recommended in current first-line therapies remains
low.
Therefore, the predicted resistance to the currently recommended first-line regimens [5]
consisting of two NRTI plus one PI or one INSTI is very low at the population level (<2.3%)
while primary resistance to NNRTI is frequent with 9.1%: 4.9% to efavirence (due to the
K103N mutation) and 6.0% to rilpivirine (due to the frequent E138A polymorphism). Similar
proportions were reported recently from the UK Drug Resistance Database with 8.2% NNRTI
resistance including 6.2% resistance to rilpivirine and 3.4% to efavirenz [36]. Resistance testing
is therefore particularly recommended for patients starting with or switching to an NNRTI-
containing regimen.
In 2017, tenofovir-containing pre-exposure prophylaxis (PrEP, e.g. tenofovir in combina-
tion with emtricitabine) was introduced in Germany. HIV-infection despite PrEP, due to
subclinical drug levels or infection with resistant variants, might occur and fuel the emergence
of TDR. So far, resistance mutations selected by tenofovir and emtricitabine (K65R, K70R
and M184V) have been rare (below 1%). However, as MSM transmission networks have been
identified to be a major source for the spread of HIV resistance by others [46] and by us, fre-
quent HIV-screening for PrEP users and the monitoring of PrEP-selected mutations is
recommended.
For the first time, we analysed, to which extent INSTI resistance was transmitted following
the introduction of the first generation INSTI raltegravir in Germany in 2007. So far, the pro-
portion of transmitted INSTI mutations is low with only one case identified. Phenotypic resis-
tance to raltegravir and elvitegravir according to Stanford HIVdb is predicted to be 0.7% and
resistance to the second generation INSTI dolutegravir was not detected at all. Primary drug
resistance to INSTIs was also described to be rare in studies of European patients diagnosed in
2013 [36] or 2015 [47]. However, since transmission of INSTI resistance in Germany might
occur with a delay the need for follow-up in the future remains.
One limitation of the present study is the relatively short study period. Changes over time
should therefore be interpreted carefully. Furthermore, integrase genotyping only started in
2014, resulting in lower PCR success rates due to RNA degradation on DSS. A combined pre-
diction including all drug classes was only possible for 43.0% of cases therefore, resistance to
integrase was analysed separately in this dataset. Another limitation is that the SDRM list has
not been updated since 2009 and resistance mutations to the newest drugs or drug classes (e.g.
integrase inhibitors) had to be analysed with different mutation lists. Some of the SDRMs are
only relevant to older drugs rarely used in today’s first-line regimens in EU/EEA countries [4,
5]. If the SDRM list is used, the weighting for TAMs is disproportionately high since they no
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longer have clinical relevance. On the other hand, NNRTI resistance is underestimated due to
the lack of the E138A mutation. The relevance of TDR for the outcome of first-line therapy in
EU/EEA countries as calculated from the SDMR list should therefore be interpreted by taking
this underestimation into consideration.
Conclusion
Despite effective cART, TDR is present at an overall stable proportion in Germany (11%). In
particular, viruses carrying resistance mutations with low fitness cost are spread continuously
by onwards transmission, and German MSM are generally driving the spread in Germany,
both within transmission networks and outside of networks as shown for the K103N mutation.
Intensified HIV-screening in these groups followed by early treatment with cART including
the pre-treatment resistance testing as recommended in the current guidelines should help
reduce the spread of resistant viruses in the ART naïve population. Due to the increasing use
of INSTIs in first-line regimens and tenofovir/emtricitabin for PrEP, it is important to monitor
TDR for public health efforts and in order to maintain the effectiveness of cART.
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